Silber S. [ESC guidelines 2019 on chronic coronary syndrome (CCS, previously “stable coronary artery disease”) : What is new? What is particularly important?] Herz. 2019;44:676-683 (in German language) your personal reprint

Silber S. [The new Disease Management Program (DMP) for patients with chronic systolic heart failure in Germany: Goals and limitations] MMW Fortschr Med. 2019;161:40-44 (in German language) your personal reprint

Siontis GC, Branca M, Serruys P, Silber S, Raber L, Pilgrim T, Valgimigli M, Heg D, Windecker S, Hunziker L. Impact of left ventricular function on clinical outcomes among patients with coronary artery disease European Journal of Preventive Cardiology. 2019;26:1273-1284 your personal reprint

Garcia-Garcia HM, McFadden EP, von Birgelen C, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P. Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention JACC Cardiovasc Interv. 2019;12:1954-1962 your personal reprint

Grammer TB, Dressel A, Gergei I, Kleber ME, Laufs U, Scharnagl H, Nixdorff U, Klotsche J, Pieper L, Pittrow D, Silber S, Wittchen HU, März W.: Cardiovascular risk algorithms in primary care: Results from the DETECT study. Sci Rep. 2019;9:1101 your personal reprint

Lindner O, Bauersachs J, Bengel FM, Burchert W, Vom Dahl J, Dorr R, Hacker M, Kelm M, Rassaf T, Rischpler C, Schafer W, Schafers MA, Silber S, Zimmermann R. [Policy paper nuclear cardiology - update 2018 - Current status of clinical practice] Kardiologe: 2018; 12: 303 - 311 und Nuklearmedizin. 2018; 57:146-152 (in German language) your personal reprint

Kische H, Hoyer J, Pieper L, Venz J, Klotsche J, Marz W, Koch-Gromus U, Pittrow D, Lehnert H, Silber S, Stalla GK, Zeiher AM, Wittchen HU, Haring R. Testosterone is not associated with traits of optimism or pessimism: Observational evidence from the prospective DETECT study. PLoS One. 2018;13:e0207870 your personal reprint

Boeckel JN, Palapies L, Klotsche J, Zeller T, von Jeinsen B, Perret MF, Kleinhaus SL, Pieper L, Tzikas S, Leistner D, Bickel C, Stalla GK, Lehner H, Lindahl B, Wittchen HU, Silber S, Baldus S, Maerz W, Dimmeler S, Blankenberg S, Münzel T, Zeiher AM, Keller T: Adjusted Troponin I for Improved Evaluation of Patients with Chest Pain Nature - Scientific Reports, 2018, 8:8087 your personal reprint

Kische H, Pieper L, Venz J, Klotsche J, Marz W, Koch-Gromus U, Pittrow D, Lehnert H, Silber S, Stalla GK, Zeiher AM, Wittchen HU, Haring R: Longitudinal change instead of baseline testosterone predicts depressive symptoms Psychoneuroendocrinology. 2018;89:7-12 your personal reprint

Silber S. Do you know your Risk of a Heart Attack ? Journal for Cardiology (Austria) (approved Reprint of the MMW publication) 2018, 25: 135-139 (in German language) your personal reprint

Silber S. Primary Prevention: Do you know your Risk of a Heart Attack ? Münchner Medizinische Wochenschrift, MMW, 2018, 160: 38-41 (in German language) your personal reprint References Cover Page: “Heart in Danger - Calculate your Risk”

Albus C, Barkhausen J, Fleck E, Haasenritter J, Lindner O, Silber S für die Leitliniengruppe NVL Chronische KHK Diagnosis of Chronic Coronary Heart Disease Clinical Guideline Deutsches Ärzteblatt, 2017; 114: 712–719 (in German language) your personal reprint Additional Material Deutsches Ärzteblatt, 2018; 115: 131–132 Discussion and Final Word (in German language) your personal reprint

Keller M, Silber S. Update Heart Attack: Warning Symptoms, Primary and Secondary Prevention Medical Journal 8/2017 (in German language) your personal reprint

Silber, S. [Suspected stable coronary artery disease - When should the general practitioner refer to a cardiologist for further evaluation and/or cardiac catheterization?] Verdacht auf stabile KHK: Wann zum Herzkatheter überweisen ? MMW - Fortschritte der Medizin, 2017; 159: 46-48 (in German language) your personal reprint

Silber, S. [Secondary prevention after myocardial infarction with prolonged dual anti-platelet therapy (DAPT). A new therapeutic concept] Thrombozytenhemmung doppelt und für drei zusätzliche Jahre ? MMW - Fortschritte der Medizin, 2017; 159: 49-52 (in German language) your personal reprint

Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program JACC Cardiovasc Interv. 2017;10:247-254 your personal reprint

Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System JACC Cardiovasc Interv. 2017;10:160-167 your personal reprint

Fajadet J, Neumann FJ, Hildick-Smith D, Petronio S, Zaman A, Spence M, Wohrle J, Elhadad S, Roberts D, Hovasse T, Valdes M, Silber S. Twelve-Month Results of A Prospective, Multicentre Trial to Assess the Everolimus-Eluting Coronary Stent System (Promus Element): The PLATINUM PLUS All Comers Randomised Trial. EuroIntervention. 2017;12:1595-1604 your personal reprint

Keller T, Boeckel JN, Gross S, Klotsche J, Palapies L, Leistner D, Pieper L, Stalla GK, Lehnert H, Silber S, Pittrow D, Maerz W, Dorr M, Wittchen HU, Baumeister SE, Volker U, Felix SB, Dimmeler S, Zeiher AM. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. Sci Rep. 2017;7:4511 your personal reprint

Di Mario C, Serruys PW, Silber S, Lu S, Wang W, Widimsky P, Xu B, Windecker S. Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program. EuroIntervention, 2016;12:1207-1214 your personal reprint

Silber S, Witzenbichler B, Vester E. [Optimal Oral Platelet Inhibition in Patients after Acute Coronary Syndrome (ACS): When to begin ? which drug ? how long ?] Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS): Wann beginnen, womit und wie lange? Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V., Update, 3. Version, Fall 2016 (in German language) your personal reprint

Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bansch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC. [Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation] Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern Herzschrittmachertherapie & Elektrophysiologie. 2016; 27:295-306 (in German language) your personal reprint

Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J, Rothenbuhler M, Stortecky S, Raber L, Blochlinger S, Hunziker L, Silber S, Juni P, Serruys PW, Windecker S. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. Am Heart J. 2016;175:56-65 your personal reprint

Abdel-Wahab M, Neumann FJ, Serruys PW, Silber S, Leon M, Mauri L, Yeung A, Belardi JA, Widimsky P, Meredith I, Saito S, Richardt G. Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program EuroIntervention, 2016, 12:465-472 your personal reprint

Piccolo R, Franzone A, Koskinas KC, Raber L, Pilgrim T, Valgimigli M, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Juni P, Heg D, Windecker S. Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2016;118:345-352 your personal reprint

Styllou P, Silber S. A case report of the new PolyzeneTM-F COBRA PzFTM Nanocoated Coronary Stent System (NCS): Addressing an unmet clinical need Cardiovasc Revasc Med, 2016; 17:209-211 your personal reprint

Belardi J, Manoharan G, Albertal M, Widimsky P, Neumann FJ, Silber S, Leon MB, Saito S. The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent. Catheter Cardiovasc Interv. 2016;87:253-261 your personal reprint

Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, Silber S, Serruys PW, Pilgrim T, Raber L, Heg D, Juni P, Windecker S. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients Circ Cardiovasc Interv. 2016;9:e003255 your personal reprint

February 2016: [National Guidelines for Medical Care of Patients with (Suspected) Coronary Artery Disease in Germany] Nationale Versorgungsleitlinien (NVL) “Chronische KHK”: Aktualisierung des Kapitels “Diagnostik bei (V.a.) KHK” (all in German language) [Full version] Gesamtfassung der NVL “Chronische KHK” [Guideline Report] Leitlinienreport Web Site of National Guidelines for Patient Care in Germany Web Site der Nationalen Versorgungsleitlinien

Silber S., Witzenbichler B, Vester E. [Optimal Oral Platelet Inhibition in Patients after Acute Coronary Syndrome (ACS): When to begin ? which drug ? how long ?] Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS): Wann beginnen, womit und wie lange? Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V., Recommendation of the Society of Interventional Cardiologists in Germany Update 2015 (in German language) your personal reprint

Vranckx P, Kalesan B, Stefanini GG, Farooq V, Onuma Y, Silber S, de Vries T, Juni P, Serruys PW, Windecker S. Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention, 2015;11:171-179 your personal reprint

Kelbaek H, Holmvang L, Richardt G, Eberli FR, Stella P, Buszman PE, Neumann FJ, Serruys PW, Windecker S, Widimsky P, Belardi JA, Silber S. Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions. EuroIntervention. 2015;11:650-657 your personal reprint

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P, investigators N. Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial. EuroIntervention. 2015;11:549-554 your personal reprint

Dudek D, Dziewierz A, Brener SJ, Abizaid A, Merkely B, Costa RA, Bar E, Rakowski T, Kornowski R, Dressler O, Abizaid A, Silber S, Stone GW. Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial. Circ Cardiovasc Interv. 2015;8:e001484 your personal reprint

Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, Zhang YJ, Mauri L, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Neumann FJ, Yeung AC, Saito S, Liu M, van Leeuwen F, Serruys PW. Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program. Catheter Cardiovasc Interv. 2015;85:952-958 your personal reprint

Piccolo R, Pilgrim T, Heg D, Franzone A, Rat-Wirtzler J, Raber L, Silber S, Serruys PW, Juni P, Windecker S. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients. JACC Cardiovasc Interv. 2015;8:1657-1666 your personal reprint

Costa RA, Abizaid A, Lotan C, Dudek D, Silber S, Dizon JM, Maehara A, Dressler O, Brener SJ, Stone GW. Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial). Am J Cardiol. 2015;115:161-166 your personal reprint

Silber S. [Comparison of Stents in Coronary Artery Disease: Completely Absorbable Stents have no Proven Advantage] Stentvergleich bei KHK: Vollständig absorbierbare Stents bringen keinen gesicherten Vorteil Dtsch Med Wochenschr. 2015;140:386 (in German language)  your personal reprint

Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial Circ Cardiovasc Interv. 2015;8:e002230 your personal reprint

Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries T, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart, 2014;100:1158-1164 your personal reprint 

Vester EG, Bocksch W, Dörr R, Grebe O, Hoffmann S, Leitsch T, Silber S. [Oral Anticoagulation für Interventional Procedures in Cardiology Recommendation of the Society of Interventional Cardiology in Germany] Orale Antikoagulation bei interventionellen Eingriffen in der Kardiologie, Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V., Summer 2014  (in German language)  your personal reprint 

Kotzerke J, Silber S. Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention Book Chapter in: Therapeutic Nuclear Medicine, Editor: Richard P. Baum, Springer-Verlag Berlin Heidelberg 2014, ISSN 0942-5373  your personal reprint 

Witt S, Leidl R, Becker C, Holle R, Block M, Brachmann J, Silber S, Stollenwerk B. The effectiveness of the cardiovascular disease prevention programme ‘KardioPro’ initiated by a German sickness fund: a time-to-event analysis of routine data. PLoS One. 2014;9:e114720  your personal reprint 

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM for the DETECT study group. Prognostic value of reported chest pain for cardiovascular risk stratification in primary care. European Journal of Preventive Cardiology. 2014;21:727-738 your personal reprint 

Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. Cardiovascular Revascularization Medicine, 2014;15:23-28 your personal reprint 

Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S. [Differentiated antiplatelet therapy for acute coronary syndromes] Differenzierte antithrombozytäre Therapie bei akutem Koronarsyndrom Dtsch Med Wochenschr, 1390: 152–158 (2014) (in German language)  your personal reprint

Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice G, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Committee ECG, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL, Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association of Percutaneous Cardiovascular I. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46:517-592 your personal reprint

Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B. Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data. BMC Health Serv Res. 2014;14:263 your personal reprint 

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63:1617-1625 your personal reprint 

Stefanini GG, Taniwaki M, Kalesan B, Raber L, Stortecky S, Pilgrim T, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S. The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents. PLoS One. 2014;9:e106450 your personal reprint 

Ferenc M, Kornowski R, Belardi J, Serruys P, Silber S, Widimsky P, Windecker S, Neumann FJ. Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. J Invasive Cardiol. 2014;26:630-638 your personal reprint

Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimsky P, Saito S, Mauri L. Performance of the resolute zotarolimus-eluting stent in small vessels. Catheter Cardiovasc Interv. 2014;84:17-23 your personal reprint 

Dudek D, Brener SJ, Rakowski T, Dziewierz A, Abizaid A, Silber S, Yaacoby E, Dizon JM, Costa RA, Maehara A, Dressler O, Stone GW. Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial). Am J Cardiol. 2014;114:1485-1489 your personal reprint 

Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.  Eur Heart J. 2014;35:1949-1956 your personal reprint

2014: [National Guidelines for Medical Care of Patients with Chronic Coronary Artery Disease in Germany] Nationale Versorgungsleitlinien (NVL) “Chronische KHK”: Aktualisierung des Kapitels “Revaskularisationstherapie” (all in German language)  [Full version] Gesamtfassung der NVL “Chronische KHK” [Guideline Report] Leitlinienreport Web Site of National Guidelines for Patient Care in Germany Web Site der Nationalen Versorgungsleitlinien

Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ. Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program. Int J Cardiol. 2013;168:3522-3526   your personal reprint 

Willich SN, Müller-Riemenschneider F, McBride D, Silber S, Kuck KH, Nienaber CA, Schneider S, Senges J, Brüggenjürgen B. Health economic evaluation of the use of drug-eluting stents : First results from the Drug-Eluting Stent Registry (DES.de). Herz, 2013; 38:57-64   your personal reprint 

Vranckx P, McFadden E, Cutlip DE, Mehran R, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW. Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation. Contemporary Clinical Trials. 2013;34:53-59   your personal reprint 

Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc Interv. 2013;6:366-377   your personal reprint 

Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P.  Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. JACC Cardiovasc Interv. 2013;6:905-913   your personal reprint 

Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM. Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol. 2013;102:259-268   your personal reprint 

Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6:334-343   your personal reprint 

Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Negoita M, van Leeuwen F, Neumann FJ, Yeung AC, Garcia-Garcia HM, Serruys PW. Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. Heart. 2013;99:626-633   your personal reprint 

Costa JR, Jr., Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial. Catheter Cardiovasc Interv. 2013;82:184-190   your personal reprint 

Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH. Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents. Clin Res Cardiol. 2013;102:289-297  your personal reprint 

Diletti R, Garcia-Garcia HM, Bourantas CV, van Geuns RJ, Van Mieghem NM, Vranckx P, Zhang YJ, Farooq V, Iqbal J, Wykrzykowska JJ, de Vries T, Swart M, Teunissen Y, Negoita M, van Leeuwen F, Silber S, Windecker S, Serruys PW Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart, 2013;99:1267-1274 your personal reprint 

Silber S, Basler M, Gerhard N: Possibilities and obstacles of the German Reimbursement System (G-DRG) for the implementation of guideline-recommended adjunctive technical devices for percutaneous coronary interventions Confluence, Issue 6, 12 - 15, (2012)   your personal reprint 

Silber S. The RESOLUTE clinical programme: one month DAPT data presented at TCT Confluence, Issue 6, 31 - 33, (2012)   your personal reprint 

Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, Marz W, Wehling M, Wittchen HU. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One. 2012;7:e52229   your personal reprint 

Vranckx P, Farooq V, Garg S, Van Es GA, Silber S, Windecker S, Stone GW, Serruys PW. Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting. Heart. 2012;98:1424-1430   your personal reprint 

Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyla R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D: Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol, 60:1975–1984 (2012)   your personal reprint 

Stefanini GG, Kalesan B, Pilgrim T, Raber L, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S. Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. JACC Cardiovasc Interv; 5:301-310 (2012)  your personal reprint 

Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W. Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines. Expert Rev Cardiovasc Ther; 10:489-503 (2012)   your personal reprint 

Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M.[Comments on the joint guidelines on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]  Kommentar zu den gemeinsamen „Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS) Der Kardiologe; 6: 94 – 104 (2012)   (in German language)  your personal reprint  Pocket Guidelines Myocardial Revascularization 

Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G. Treatment of coronary bifurcation lesions with drug-eluting stents: Insights from the first phase of the prospective multicenter german drug-eluting stent registry. J Interv Cardiol. 2012;25:344-352   your personal reprint 

Beijk MA, Damman P, Klomp M, Woudstra P, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter AR. Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered R stent in patients with a bifurcation lesion: From the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) registry. Coronary Artery Disease; 23:201-207 (2012)   your personal reprint 

Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ. Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous bio-engineered R stent in patients from the e-HEALING registry. Catheter Cardiovasc Interv; 79:243-252 (2012)   your personal reprint 

Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ. Applying the national institute for clinical excellence criteria to patients treated with the genous bio-engineered R stent: A sub-study of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry. Heart Vessels; 27:360-369 (2012)   your personal reprint 

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM. Resting heart rate as a tool for risk stratification in primary care: Does it provide incremental prognostic information? European Journal of Preventive Cardiology; 19:275-284 (2012) your personal reprint 

Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem; 58:200-208 (2012)   your personal reprint 

Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ. Differences in cardiovascular risk factors and clinical outcomes between western european and southeast asian patients treated with the genous bio-engineered R stent: An e-HEALING worldwide registry substudy. Coronary Artery Disease; 23:271-277 (2012)   your personal reprint 

Silber S, Tan HC, Iniguez A, Scacciatella P, Smith D, Kutryk M, Brugaletta S  Relative clinical contraindications to the use of drug-eluting stents: what are the alternatives? Cardiology International, 45 - 48 (2012)   your personal reprint 

Schneider HJ, Klotsche J, Friedrich N, Schipf S, Volzke H, Silber S, Marz W, Nauck M, Pittrow D, Wehling M, Sievers C, Lehnert H, Stalla GK, Wittchen HU, Wallaschofski H. Risk factors associated with the metabolic syndrome in abdominal obesity. Clin Obes. 2012;2:142-149   your personal reprint 

Silber S, Helms T, Berger H-J, Braun P, Hoffmann S, Schäfer A, Vester E. [Optimal Platelet Inhibition in Patients with Acute Coronary Syndrome (ACS)] Optimale Thrombozytenaggregationshemmung bei Patienten mit akutem Koronarsyndrom (ACS). Recommendations of the Society of Inverventional Cardiology in Germany 1st Version, Spring 2012 (in German language)  your personal reprint 

Silber S, Schuhbeck A: [The Right Nutrition for Heart and Circulation] Book Chapter in: A. Schuhbeck: Die Heilkraft von Omega-3, Seiten 24 - 27 Verlag Zabert Sandmann GmbH, München, 1. Auflage 2011, ISBN 978-3-89883-273-1 (in German language)  your personal reprint 

[National Guidelines for Patient Care in Germany regarding Chronic Coronary Artery Disease] Nationale Versorgungsleitlinien der Bundesärztekammer, Kassenärztlichen Bundesvereinigung und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zur chronischen koronaren Herzkrankheit 2011 (in German language)  www.versorgungsleitlinien.de

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the EURO HEART survey PCI registry. Catheter Cardiovasc Interv; 78:702-709 (2011)   your personal reprint 

Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R. Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: Results from the German DES.DE-Registry. Clin Res Cardiol; 100:701-709 (2011) your personal reprint

Damman P, Iniguez A, Klomp M, Beijk M, Woudstra P, Silber S, Ribeiro EE, Suryapranata H, Sim KH, Tijssen JG, de Winter RJ. Coronary stenting with the genous bio-engineered R stent in elderly patients. Circ J; 75:2590-2597 (2011) your personal reprint

Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.  Twelve-month outcomes after coronary stenting with the genous bio-engineered R stent in diabetic patients from the e-HEALING registry. J Interv Cardiol; 24:285-294 (2011) your personal reprint 

De Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, Boersma E. Euroheart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. Eur Heart J; 32:1398-1408 (2011) your personal reprint 

den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ. Final results of the HEALING-IIb trial to evaluate a bio-engineered cd34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Atherosclerosis; 219:245-252 (2011) your personal reprint

Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S. The prognostic utility of the syntax score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial. JACC Cardiovasc Interv; 4:432-441 (2011)   your personal reprint 

Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW. Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. Am Heart J; 162:1069-1079 e1062 (2011) your personal reprint

Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the resolute all comers trial. Eur Heart J; 32:2454-2463 (2011) your personal reprint

Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU. Measuring abdominal obesity: Effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio. Diabetes Care; 34:e7 (2011) your personal reprint

Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Hian Sim K, Tijssen JG, de Winter RJ. Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry. EuroIntervention; 6:819-825 (2011) your personal reprint

Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Chevalier B, Serruys PW. Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial. EuroIntervention; 7:64-73 (2011) your personal reprint

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]  Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand? Dtsch Med Wochenschr; 136:782-785 (2011)   (in German language)  your personal reprint 

Silber S, Windecker S, Vranckx P, Serruys PW.  Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial Lancet; 377:1241-1247 (2011)   your personal reprint 

Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol; 57:2221-2232 (2011) your personal reprint

Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, Agostoni P, Sangiorgi G, Silber S.  The VALENTINES trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation dior paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention; 7:705-710 (2011) your personal reprint

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK. Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. Int J Cardiol; 151:164-169 (2011) your personal reprint 

Silber S. Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines RMMJ; 2: e0056 (2011)   your personal reprint 

Silber S,Van de Werf F. and Members of the Task Force ESC/DGK Pocket-Leitlinie: Akutes Koronarsyndrom mit persistierender ST- Streckenhebung (STEMI)  Der Kardiologe; 4:93-106 (2010) your personal reprint 

Silber S, Borggrefe M, Hasenfuß G, Falk V, Kastrati A, Weis M, Hamm CW. [Commentary on the guidelines of the European Society of Cardiology (ESC) regarding the diagnosis and treatment of patients with ST-segment elevation myocardial infarction (STEMI)]  Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI) Der Kardiologe; 4:84-92 (2010) (in German language)  your personal reprint 

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK. Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics. Clin Res Cardiol; 99:375-383 (2010) your personal reprint

Mahabadi AA, Achenbach S, Burgstahler C, Dill T, Fischbach R, Knez A, Moshage W, Richartz BM, Ropers D, Schröder S, Silber S, Möhlenkamp S. Safety, efficacy, and indications of beta-adrenergic receptor blockade to reduce heart rate prior to coronary ct angiography. Radiology; 257:614-623 (2010) your personal reprint

Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, Wallaschofski H, Wittchen HU. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab; 95:1777-1785 (2010) your personal reprint

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med; 363:136-146 (2010)  your personal reprint Originalarbeit your personal reprint Appendix

Silber S.  [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010 ] Evidenzbasiertes Vorgehen beim ST-Strecken- Hebungsinfarkt (STEMI): Neueste Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) 2010 Herz; 35:558-564 (2010) (in German language)  your personal reprint

Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention; 5:871-874 (2010) your personal reprint

Hoffmeister HH, Bode C, Darius H, Huber K, Rybak K, Silber S. [Bridging of Antithrombotic Therapy in Patients with Cardiovascular Disease. Position paper of the German Society of Cardiology ] Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen Positionspapier der Deutschen Gesellschaft für Kardiologie (DGK) Der Kardiologe; 4: 365-374 (2010) (in German language)  your personal reprint

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC) Eur Heart J; 31:2501-2555 (2010) your personal reprint Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52 your personal reprint